Gene · 51185
Papers2,935
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
641 to 660 of 2,935
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Proteolysis-Targeting Chimera (PROTAC) Delivery into the Brain across the Blood-Brain Barrier. | Antibodies (Basel) | 2023 | 37489365 | PubTator, text mining | PubMed |
| Enhancement of the SESN2-SHP cascade by melatonin ameliorates hepatic gluconeogenesis by inhibiting the CRBN-BTG2-CREBH signaling pathway. | Exp Mol Med | 2023 | 37488285 | PubTator, text mining | PubMed |
| Beyond canonical PROTAC: biological targeted protein degradation (bioTPD). | Biomater Res | 2023 | 37480049 | PubTator, text mining | PubMed |
| Cardiovascular toxicity from therapies for light chain amyloidosis. | Front Cardiovasc Med | 2023 | 37476571 | PubTator, text mining | PubMed |
| Determination of Ligand-Binding Affinity (Kd) Using Transverse Relaxation Rate (R2) in the Ligand-Observed 1H NMR Experiment and Applications to Fragment-Based Drug Discovery. | J Med Chem | 2023 | 37467168 | PubTator, text mining | PubMed |
| Mechanism and therapeutic implications of pomalidomide-induced immune surface marker upregulation in EBV-positive lymphomas. | Sci Rep | 2023 | 37463943 | PubTator, text mining | PubMed |
| Histone Methyltransferase NSD2 Activates PKCα to Drive Metabolic Reprogramming and Lenalidomide Resistance in Multiple Myeloma. | Cancer Res | 2023 | 37463241 | PubTator, text mining | PubMed |
| Incidence of cereblon protein in intensive care patients: a cross-sectional study. | Eur Rev Med Pharmacol Sci | 2023 | 37458657 | PubTator, text mining | PubMed |
| Discovery and Characterization of PROTACs Targeting Tissue Transglutaminase (TG2). | J Med Chem | 2023 | 37449845 | PubTator, text mining | PubMed |
| Development of the first geldanamycin-based HSP90 degraders. | Front Chem | 2023 | 37448856 | PubTator, text mining | PubMed |
| Molecular Glue Discovery: Current and Future Approaches. | J Med Chem | 2023 | 37437222 | PubTator, text mining | PubMed |
| Clinician's guide to targeted estrogen receptor degradation using PROTAC in patients with estrogen receptor-positive metastatic breast cancer. | Curr Opin Oncol | 2023 | 37427531 | PubTator, text mining | PubMed |
| Targeting histone deacetylases for cancer therapy: Trends and challenges. | Acta Pharm Sin B | 2023 | 37425042 | PubTator, text mining | PubMed |
| Discovery of novel exceptionally potent and orally active c-MET PROTACs for the treatment of tumors with MET alterations. | Acta Pharm Sin B | 2023 | 37425039 | PubTator, text mining | PubMed |
| T Cell-intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia. | Mol Cancer Ther | 2023 | 37420267 | PubTator, text mining | PubMed |
| A Modular Chemistry Platform for the Development of a Cereblon E3 Ligase-Based Partial PROTAC Library. | Chembiochem | 2023 | 37418320 | PubTator, text mining | PubMed |
| A model-informed method to retrieve intrinsic from apparent cooperativity and project cellular target occupancy for ternary complex-forming compounds. | RSC Chem Biol | 2023 | 37415863 | PubTator, text mining | PubMed |
| Expanding Chemical Probe Space: Quality Criteria for Covalent and Degrader Probes. | J Med Chem | 2023 | 37403870 | PubTator, text mining | PubMed |
| Antiviral PROTACs: Opportunity borne with challenge. | Cell Insight | 2023 | 37398636 | PubTator, text mining | PubMed |
| Single amino acid-based PROTACs trigger degradation of the oncogenic kinase BCR-ABL in chronic myeloid leukemia (CML). | J Biol Chem | 2023 | 37392851 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51185/papers?page=33